Tomm34 klrqevkqnl

HLA‐A*2402‐restricted RNF43 (NSQPVWLCL) and TOMM34 (KLRQEVKQNL) peptides were synthesized by the American Peptide Company (Sunnyvale, CA, USA) according to a standard solid‐phase synthesis method; preclinical trials previously confirmed that the peptides did not produce acute toxicity.8 UFT is a relatively old oral fluoropyrimidine that was developed in Japan in the 1980s. It has many indications for metastatic and advanced solid cancers, including those of the colon, lung, breast, and pancreas, and gastric cancer.10 In metastatic CRC, UFT/LV was demonstrated to have the same clinical efficacy as 5‐FU/LV and comparable pharmacokinetics between Japanese and US patients.11, 12, 13

HLA-A*2402-restricted RNF43 (NSQPVWLCL) and TOMM34 (KLRQEVKQNL) peptides were synthesized by American Peptide Company Inc. (Sunnyvale, CA, USA) according to a standard solid-phase synthesis method; preclinical trials previously confirmed that the peptides did not produce acute toxicity (13 (link)).
Montanide ISA-51 (also known as incomplete Freund's adjuvant) is a sterile vaccine adjuvant manufactured by SEPPIC Co. (Puteaux, France) in accordance with good manufacturing practice standards. Montanide is currently used as an adjuvant in vaccine therapies worldwide, and no serious adverse events caused by Montanide have been reported.
UFT is a relatively old oral fluoropyrimidine that was developed in Japan in the 1980s. It has many indications for metastatic and advanced solid cancers including those of the colon, lung, breast, and pancreas, and gastric cancer (14 (link)). In metastatic CRC, UFT/LV was demonstrated to have the same clinical efficacy as 5-FU/LV and comparable pharmacokinetics between Japanese and American patients (15 (link)–17 (link)). We previously demonstrated that the standard dose of UFT/LV did not impede the immune responses of patients with advanced CRC to peptides administered as cancer vaccination (18 (link)).